A Study of LY3108743 in Healthy Participants and Participants With Type 2 Diabetes

Phase 1

Completed

Interventions: Drug: Placebo - Capsule
Drug: LY3108743 - Capsule
Drug: Placebo - Solution
Drug: LY3108743 - Solution

Brief Summary: The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY3108743 in healthy participants and in participants with type 2 diabetes.

The study will also investigate how LY3108743 affects the levels of blood sugar and other naturally occurring substances (e.g. hormones that control the way sugar is used) in the body, how much of the study drug gets into the blood stream, and how long it takes the body to get rid of it.

Information about any side effects that may occur will be collected. The study is expected to last approximately 7 to 8 weeks for each participant.

The study will have up to 3 parts. Participants may enroll in only one part.

Recruitment & Eligibility

Inclusion Criteria

Must be a male, or a female who cannot become pregnant, and who is either a healthy participant, or who has type 2 diabetes
Have a body mass index (BMI) of 18.5 to 40.0 kilogram per square meter (kg/m^2), inclusive, at screening
Have normal blood pressure
Participants with diabetes must not be taking any anti-hyperglycemic medications with the exception of metformin. If on metformin, participants must be on a stable treatment regimen for at least for 4 weeks prior to screening
Participants with diabetes must have a hemoglobin A1c (HbA1c) level between 6 to 11%, inclusive, at screening

Exclusion Criteria

Have previously completed or withdrawn from this study
Have or used to have health problems or laboratory test results or electrocardiogram (ECG) readings that, in the opinion of the doctor, could make it unsafe to participate or could interfere with understanding the results of the study

Arm && Interventions

Group	Intervention	Description
Placebo - Healthy	Placebo - Capsule	Part A. Healthy participants will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
LY3108743 - Diabetes	LY3108743 - Capsule	Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
LY3108743 - Healthy	LY3108743 - Capsule	Part A. Healthy participants will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
Placebo - Solution	Placebo - Solution	Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of placebo matching LY3108743 in 1 of 2 study periods.
Placebo - Diabetes	Placebo - Capsule	Part B. Participants with diabetes mellitus will receive a single oral dose of placebo matching LY3108732 in at least 1 of 3 study periods.
LY3108743 - Solution	LY3108743 - Solution	Part C. Contingent on results from Parts A and B. Healthy participants will receive a single oral dose of LY3108743 in 1 of 2 study periods.

Primary Outcome Measures

Name	Time	Method
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration	Pre-dose up to Day 6 (5 days post-dose)

Secondary Outcome Measures

Name	Time	Method
Maximum Change from Baseline up to 24 Hours in Level of Blood Glucose Before and After a Standard Meal	Baseline up to 24 hours
Pharmacokinetics: Maximum Concentration (Cmax) of LY3108743	Baseline up to 48 hours
Pharmacokinetics: Area Under the Curve (AUC) of LY3108743	Baseline up to 48 hours

Locations (1): For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇸🇬
Singapore, Singapore

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial